About this trial
evaluate the combined effects of Rutin and Vitamin C versus Vitamin C alone on selected oxidative stress markers, inflammation, hepatic steatosis regression, and associated metabolic parameters in patients with MASLD
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Confirmed diagnosis of Metabolic-Associated Steatotic Liver Disease (MASLD).
Disqualifiers
HCV infection.
HBV infection.
Patients with a history of significant alcohol consumption.
Autoimmune hepatitis.
Trial design
Parallel
Treatments tested in this trial
Rutin + Vitamin C
DrugType: Drug (Combination therapy) Details: Oral administration of two tablets containing 60 mg Rutin + 160 mg Vitamin C, taken three times daily for 12 weeks.
Vitamin C 500mg
DrugType: Drug (Single agent) Oral administration of Vitamin C 500 mg, taken twice daily for 12 weeks
Lifestyle Intervention
BehavioralMediterranean diet focusing on fruits, vegetables, whole grains, healthy fats, plus structured exercise program for 12 weeks.
Treatment groups
Trial outcomes
Primary outcomes
• Change in tumor necrosis factor-alpha (TNF-α) levels from baseline to week 12.
Serum TNF-α, a key biomarker of inflammation in MASLD
Secondary outcomes
• Change in serum malondialdehyde (MDA) levels from baseline to week 12.
Malondialdehyde (MDA) is a well-established biomarker of oxidative stress in MASLD, reflecting lipid peroxidation and liver injury.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: